期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

凝血酶激活的纤溶抑制物编码区基因位点C1040T和G505A单核苷酸多态性与脑梗死的相关性研究 被引量：1

Association Between Thrombin-activatable Fibrinolysis Inhibitor Encoding Gene CPB2 Thr325Ile(C1040T) and Thr147Ala(G505A) Polymorphisms and Cerebral Infarction
下载PDF
导出
摘要 目的:研究凝血酶激活的纤溶抑制物(TAFI)编码区CPB2基因位点C1040T和G505A的单核苷酸多态性与脑梗死之间的联系。方法:应用聚合酶链反应和限制性内切酶片段长度多态性分析技术(PCR-RFLP)检测98例脑梗死患者和100名正常对照者的TAFI基因编码区C1040T(Thr325Ile)、G505A(Thr147Ala)多态性分布特点。结果:CPB2基因C1040T(Thr325Ile)及G505A(Thr147Ala)2个位点的3种基因型在脑梗死组和对照组的频率分布分别为C1040C(Thr325Thr)33(33.7%)、29(29.0%);C1040T(Thr325Ile)47(48.0%)、51(51.0%);T1040T(Ile325Ile)18(18.3%)、20(20.0%);A505A(Thr147Thr)15(15.3%)、43(43.0%);G505A(Thr147Ala)44(45.0%)、19(19.0%);G505G(Ala147 Ala)39(39.7%)、38(38.0%)。经χ2检验,基因型分布符合Hardy-Weinberg平衡,并且脑梗死组与对照组之间各种基因型频率分布差异无统计学意义(P>0.05)。结论:TAFI编码区CPB2基因(Thr325Ile、Thr147Ala)的多态性与脑梗死的发生无明显相关性。 Objective： To investigate the polymorphism of thrombin-activatable fibrinolysis inhibitor（TAFI）encoding gene CPB2 in patients with cerebral infarction（CI）.Methods： CPB2 gene（Thr325Ile and Thr147Ala）polymorphism was typed with polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） in patients with CI（n=98） and a control group（n=100）.Results： The genotype frequencies of Thr325Ile（C1040T） and Thr147Ala（G505A） in the CI group and control group were as follows： C1040C（Thr325Thr）of 33（33.7%）and 29（29.0%）;C1040T（Thr325Ile）of 47（48.0%）and 51（51.0%）;T1040T（Ile325Ile）of 18（18.3%）and 20（20.0%）;A505A（Thr147Thr）of 15（15.3%）and 43（43.0%）;G505A（Thr147Ala） of 44（45.0%）and 19（19.0%）;and G505G（Ala147 Ala）of 39（39.7%）and 38（38.0%）.χ2 analysis showed no significant difference in all the Thr325Ile and Thr147Ala polymorphism distributions in the CI and control groups（P0.05）.Conclusion： None of the results showed any statistical correlation between TAFI polymorphisms and CI.
作者 石磊 王丽丽 李召东 王苗国 石鑫 徐成伟
机构地区 浙江省肿瘤医院化疗科 浙江省中西医结合医院检验科 浙江大学附属第二医院 山东大学附属第二医院检验科
出处 《浙江中西医结合杂志》 2011年第3期149-152,共4页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
关键词 脑梗死 凝血酶激活的纤溶抑制物 PCR-RFLP CPB2基因 单核苷酸多态性 cerebral infarction thrombin-activatable fibrinolysis inhibitor（TAFI）polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） CPB2 gene polymorphism
分类号 R743.3 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献7

  • 1Franco. RF,Fagundes MG,Meijers JC,et aL Identification of polymorphisms in the 5"-untranslate dregion of the TAFI gene relationship with plasma TAFI levels and risk of venous thrombosis[J].Haematologica,2001,86(5):510-517.
  • 2Michael BB, Marlys LK. Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor(TAFI)and in understanding its molecular genetics, gene regulation,and biological roles (review)[J]. Clinical Biochemistry, 2007, 40 (5):431-442.
  • 3Bjorkman JA, Abrahamsson TI, Nerme VK, et al. Inhibition of carboxypeptidase U(TAFIa) activityimproves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis[J]. Thromb Res,2005,116(6):519-524.
  • 4陈煜森,赵斌,许志恩,山■英久,三木哲郎.TAFI基因编码区的单核苷酸多态性与脑梗死的相关性探讨[J].神经疾病与精神卫生,2003,3(6):419-421. 被引量：3
  • 5Juhan-Vague I, Morange PE, Aubert H, et al.Plasma thrombinactivatable fibfinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe[J]. Arterioscler Thromb Vasc Biol, 2002, 22(5 ) : 867-873.
  • 6Morange PE, Tregouet DA,FRERE C,et al. TAFI gene hap- lotypes, TAFI plasma levels and future risk of coronary heart disease: the prime study[J]. J Thromb Haemost,2005,3(7): 1503-1510.
  • 7Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding re- gion of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels[J]. Blood,2001,98 (6):1992-1993.

二级参考文献16

  • 1[1]Bajzar L, Nesheim ME, Tracy PB ,et al. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI- dependent[J]. Blood, 1996,88 (6): 2 093 - 2 100.
  • 2[2]Sakharov DV, Plow EF, Rijken DC, et al. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B[J]. The Journal of Biological Chemistry, 1997, 272 (22): 14 477-14 482.
  • 3[3]Wang W, Boffa MB, Bajzar L ,et al. A study of the mecha nism of inhibition of fibrinolysis by activated thrombin- acti vatable fibrinolysis inhibitor [J]. The Journal of Biological Chemistry,1998,273(42) :27 176-21 781.
  • 4[4]Boffa MB, Reid TS, Joo E ,et al. Characterization of the gene encoding human TAFI (Thrombin- activable fibrinolysis in hibitor; plasma procarboxypeptidase B) [J]. Biochemistry, 1999,38(20) :6 547-6 558.
  • 5[5]Zhao L, Morser J, Bajzar L, et al. Identification and charac terization of two thrombin- activatable fibrinolysis inhibitor isoforms[J]. Thrombosis Haemostasis, 1998, 80 (6) : 949 - 955.
  • 6[6]Minnema MC, Friederich PW, Levi M, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor Ⅺ: in vivo evidence for a role of factor Ⅺ as an anti-fibrinolytic factor[J]. The Journal of Clinical Investigation, 1998, 101 (1) :10-14.
  • 7[7]Nagashima M, Werner M, Wang M, et al. An inhibitor of ac tivated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model[J]. Thrombosis Re seach, 2000,98(4) :333-342.
  • 8[8]Van Tilburg NH, Rosendaal FR, Bertina RM ,et al. Throm bin activable fibrinolysis inhibitor and the risk for deep vein thrombosis[J]. Blood,2000,95(9) :2 855-2 859.
  • 9[9]Juhan-Vague I, Renucci JF, Grimaux M, et al. TAFI anti gen levels and cardiovascular risk factors. Arteriosclerosis[J]. Thrombosis and Vascular Biology,2000,20(9):2 156-2 161.
  • 10[10]Juhan-Vague I, Morange PE, Aubert H, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen con centration and genotype in relation to myocardial infarc tion in the north and south of Europe[J]. Arteriosclero sis, Thrombosis and Vascular Biology, 2002,22 (5): 867 - 873.

共引文献2

同被引文献2

引证文献1

浙江中西医结合杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部